Evercore analyst Liisa Bayko upgrades $Editas Medicine (EDIT.US)$ to a buy rating, and maintains the target price at $7.
According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of 10.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The company's third-quarter outcomes were supplementary to the earlier strategic update, according to the analyst.
The primary discussion among investors regarding Editas Medicine centers on determining if the company's new strategy represents progress or a regression. However, it is believed that reni-cel for sickle cell disease and transfusion-dependent thalassemia stands as a de-risked asset with potential for monetization. This asset also provides crucial insights that could be advantageous as management deliberates future approaches for their in vivo candidate.
Editas Medicine's emphasis on in vivo HSPC editing is still viewed as a strategic and efficient allocation of its expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline updates anticipated in the first quarter of 2025, along with further developments on reni-cel BD activity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析师Liisa Bayko上调$Editas Medicine (EDIT.US)$至买入评级，维持目标价7美元。
根据TipRanks数据显示，该分析师近一年总胜率为45.8%，总平均回报率为10.6%。
此外，综合报道，$Editas Medicine (EDIT.US)$近期主要分析师观点如下：
分析师称，该公司第三季度的业绩是对先前战略更新的补充。
投资者关于Editas Medicine的主要讨论集中在确定公司的新战略是进步还是倒退。但是，据信，治疗镰状细胞病和依赖输血的地中海贫血的reni-cel是一种无风险资产，具有获利潜力。该资产还提供了重要的见解，在管理层为其体内候选人考虑未来的方法时，这些见解可能具有优势。
Editas Medicine对体内HSPC编辑的重视仍被视为其专业知识和资源的战略和有效分配，以创造价值。预计将于2025年第一季度进行的体内产品线更新以及reni-cel BD活动的进一步发展，人们的期望越来越高。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
